Today’s Research Reports on Trending Tickers: Geron Corporation and Amicus Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / January 30, 2018 / U.S. markets posted their worst day of 2018 on Monday as the yield on the benchmark 10-year Treasury note traded at the highest level since April 2014. The Dow Jones Industrial Average fell 0.67 percent to close at 26,439.48, while the S&P 500 Index declined 0.67 percent to close at 2,853.53. The Nasdaq Composite Index dropped 0.52 percent to close at 7,466.51.
"The rebound in the dollar and of course with the 10-year yield at 2.71[%] that's a little bit of a challenge for the market here, especially if we continue to rise," said Peter Cardillo, chief market economist at First Standard Financial, according to MarketWatch.
RDI Initiates Coverage on:
Geron Corporation
https://rdinvesting.com/news/?ticker=GERN
Amicus Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=FOLD
Geron's stock jumped 16.34% on Monday, to close the day at $2.35. The stock recorded a trading volume of 6,384,388 shares, which was above its three months average volume of 1,676,196 shares. In the last year, Geron's shares have traded in a range of 1.74 - 3.15. The share price has gained 35.06% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.93 is below its 200-day moving average of $2.12. Shares of Geron have gained roughly 30.56 percent in the past month.
Access RDI's Geron Corporation Research Report at:
https://rdinvesting.com/news/?ticker=GERN
On Monday, shares of Amicus Therapeutics recorded a trading volume of 6,076,473 shares, which was above the three months average volume of 2,339,106 shares. The stock ended the day 2.78% higher at 16.65. The share price has gained 228.40% from its 52 week low with a 52 week trading range of 5.07 - 17.40. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $14.73 is greater than its 200-day moving average of $13.88. Shares of Amicus Therapeutics have gained roughly 15.71 percent in the past month.
Access RDI's Amicus Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FOLD
Our Actionable Research on Geron Corporation (NASDAQ:GERN) and Amicus Therapeutics, Inc. (NASDAQ:FOLD) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
